We are live on ! Find out more
DFTX

Definium Therapeutics
DFTX

84 hedge funds and large institutions have $13.9M invested in Definium Therapeutics in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

905% more call options, than puts

Call options by funds: $9.99M | Put options by funds: $994K

11% more capital invested

Capital invested by funds: $12.6M → $13.9M (+$1.34M)

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.28% less ownership

Funds ownership: 10.36% → 10.08% (-0.28%)

5% less funds holding

Funds holding: 88 → 84 (-4)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

Holders
84
Holders Change
-4
Holders Change %
-4.55%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
13
Reduced
12
Closed
11
Calls
$9.99M
Puts
$994K
Net Calls
+$9M
Net Calls Change
+$217K

Top Buyers

1
CAM
Cresset Asset Management
Illinois
+$550K
2
BlackRock
BlackRock
New York
+$350K
3
CIC
Cornercap Investment Counsel
Georgia
+$195K
4
Group One Trading
Group One Trading
Illinois
+$173K
5
Millennium Management
Millennium Management
New York
+$161K

Top Sellers

1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$847K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$800K
3
Renaissance Technologies
Renaissance Technologies
New York
-$66.5K
4
Citadel Advisors
Citadel Advisors
Florida
-$51K
5
PCM
Prelude Capital Management
New York
-$39.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
CWA
51
Clearview Wealth Advisors
Oregon
$236 – – –
HCM
52
Hollencrest Capital Management
California
$236 – – –
US Bancorp
53
US Bancorp
Minnesota
$236 – – –
WIM
54
Westside Investment Management
California
$236 – – –
TCM
55
Tradewinds Capital Management
Washington
$190 – – –
IPW
56
Impact Partnership Wealth
Georgia
$171 +$166 +48 New
PMFA
57
Plante Moran Financial Advisors
Michigan
$129 – – –
Northwestern Mutual Wealth Management
58
Northwestern Mutual Wealth Management
Wisconsin
$118 -$114 -33 -50%
CAM
59
Chesapeake Asset Management
New York
$117 – – –
GEA
60
Glen Eagle Advisors
New Jersey
$108 – – –
IA
61
IFP Advisors
Florida
$107 – – –
HWM
62
HighMark Wealth Management
Minnesota
$104 – – –
AAP
63
Arax Advisory Partners
Colorado
$100 – – –
AWM
64
Avior Wealth Management
Nebraska
$85 – – –
JP Morgan Chase
65
JP Morgan Chase
New York
$75 – – –
PP
66
Pacifica Partners
Canada
$75 – – –
FCA
67
FinTrust Capital Advisors
South Carolina
$73 – – –
GI
68
Gradient Investments
Minnesota
$64 -$69 -20 -53%
NC
69
NewSquare Capital
Pennsylvania
$61 – – –
SIC
70
SJS Investment Consulting
Ohio
$50 – – –
CB
71
CNB Bank
Pennsylvania
$36 – – –
FWM
72
Focused Wealth Management
New York
$36 – – –
HI
73
Harbour Investments
Wisconsin
$36 – – –
JWM
74
Janiczek Wealth Management
Colorado
$36 – – –
AssetMark Inc
75
AssetMark Inc
California
$29 +$28 +8 New
1 2
3
4

DFTX Hedge Fund Activity: Q2 2023 in Review

84 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2023, worth a combined $13.9M — up 11% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of DFTX and 8 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 13 added.

The largest buyer was Cresset Asset Management, opening a new position worth an estimated $550K. The largest seller was Alyeska Investment Group, cutting an estimated $847K.

  • 84 institutional investors held Definium Therapeutics (DFTX) as of Q2 2023, down from 88 in Q1 2023.
  • Funds reported $13.9M of Definium Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
  • 8 funds opened new Definium Therapeutics positions in Q2 2023 and 11 closed out, a net change of -3 holders.
  • The largest Definium Therapeutics buyer in Q2 2023 was Cresset Asset Management, an estimated $550K added.
  • The largest Definium Therapeutics seller in Q2 2023 was Alyeska Investment Group, an estimated $847K sold.

Based on aggregated 13F filings for Q2 2023.